Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.58 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.58 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.52 |
| ▸ | CCKBR | P32239 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17446812 | 1.00 | KMT2A (0.62) | KMT2AMEN1ALDH1A1HPGDSIRT2 | |
| SCHEMBL17446732 | 1.00 | KMT2A (0.62) | KMT2AMEN1ALDH1A1HPGDSIRT2 | |
| SCHEMBL17832976 | 0.94 | KMT2A (0.64) | KMT2AMEN1ALDH1A1HPGDSIRT2 | |
| SCHEMBL17446648 | 0.93 | PSMB5 (0.58) | KMT2AMEN1ALDH1A1HPGDSIRT2 | |
| SCHEMBL23497308 | 0.92 | KMT2A (0.64) | KMT2AMEN1ALDH1A1HPGDSIRT2 | |
| SCHEMBL22684688 | 0.92 | KMT2A (0.64) | KMT2AMEN1ALDH1A1HPGDSIRT2 | |
| SCHEMBL22577401 | 0.92 | KMT2A (0.64) | KMT2AMEN1ALDH1A1HPGDSIRT2 | |
| SCHEMBL22684690 | 0.92 | KMT2A (0.64) | KMT2AMEN1ALDH1A1HPGDSIRT2 | |
| SCHEMBL22577402 | 0.92 | KMT2A (0.64) | KMT2AMEN1ALDH1A1HPGDSIRT2 | |
| SCHEMBL23497307 | 0.92 | KMT2A (0.64) | KMT2AMEN1ALDH1A1HPGDSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210778-A1 | NOVEL COMPOUNDS | INVIVOGEN SAS (FR) | 2017-07-27 | — | — | US | disclosed |
| WO-2016008946-A1 | NOVEL COMPOUNDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2016-01-21 | — | — | WO | disclosed |
| EP-2975046-A1 | Novel compounds | The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth (IE) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210778-A1 | NOVEL COMPOUNDS | F12, C1R, F11 | KMT2A 4320/4885MEN1 76/4885ALDH1A1 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.